tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Imugene Expands Market Presence with New Securities Quotation

Story Highlights
Imugene Expands Market Presence with New Securities Quotation

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Imugene ( (AU:IMU) ) is now available.

Imugene Limited has announced the quotation of 7,335,608 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 1, 2025. This move is part of a previously announced transaction, which may enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is engaged in creating novel cancer treatments that harness the immune system to target and eradicate tumors, positioning itself as a key player in the cancer treatment market.

YTD Price Performance: -77.34%

Average Trading Volume: 1,750,636

Technical Sentiment Signal: Sell

Current Market Cap: A$82.22M

Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1